PredicineATLAS™

600-gene CLIA-certified cfDNA assay for comprehensive variant profiling, TMB & MSI assessment

• Detects SNVs, Indels, rearrangement, and copy number gain

• Identifies gene deletion and mono- vs. bi-allelic loss of function

• CLIA-certified assay for blood and tissue

• Adopted by leading biopharmas in global clinical trials

 

Features and benefits

Broadest gene coverage (TMB, MSI, HRD)

Low sample input
≥ 0.4mL

Liquid and tissue flexibility

Actionable results and data interpretation

Sample types

Whole blood
Plasma
Urine
FFPE

Sample requirements

10ml whole blood*
4ml plasma (down to 0.4ml)
40ml urine
10 FFPE slides

Turnaround time

10 days

*CLIA-certified assay requires two tubes of 10mL whole blood

Molecular insights to guide immuno-oncology and targeted therapy

PredicineATLAS™ assay is designed to help biopharmaceutical partners identify patients with the right molecular profile for their clinical program, assess response to investigational drugs or combination therapies, and detect presence of residual disease, recurrence, or relapse.  

Longitudinal analysis of cfDNA for disease progression and treatment response

In clinical studies, PredicineATLAS showed high performance in longitudinal assessment of cfDNA across multiple solid tumors to identify patients responding to therapeutics.  The data here demonstrates a deep reduction in variant allele frequency (VAF) among responders to immune checkpoint inhibitor therapy in biliary tract cancer.1  

Workflow

PILOT PROGRAM

We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and we will respond within 24 hours.

SEE OTHER TESTS  

    References

    1Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). Do-Youn Oh et al. Journal of Clinical Oncology 2020 38:15_suppl, 4520-4520